Celonic acquires Glycotope’s biomanufacturing facility

3 Nov 2017

Combined technology assets will provides pharmaceutical and biotech customers the unique opportunity to select a tailored expression system.

Celonic and Glycotope have announced the successful completion of Celonic’s acquisition of Glycotope’s biomanufacturing facility in Heidelberg, Germany.

Celonic acquires Glycotope’s biomanufacturing facility

The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets and innovative technology platforms. The acquisition is expected to accelerate topline growth, driven by expanded GMP manufacturing assets and by an immediate investment in capacity for late-stage and commercial supply.

Dr Konstantin Matentzoglu, Celonic's CEO, said: "With on-boarding of almost two decades of invaluable experience in optimization of perfusion continuous manufacturing processes, Celonic is well positioned to offer our customers the flexibility and the advantages of perfusion and fed-batch manufacturing – from pilot to commercial scale.”

“Also, adding Glycotope’s highly complementary GEX human cell line platform to Celonic’s innovative CHOvolution integrated development platform gives our pharmaceutical and biotech customers the unique opportunity to select a tailored expression system, suitable for their bio-therapeutics development needs.”

Dr Franzpeter Bracht, former COO of Glycotope and future COO of Celonic added “The Heidelberg site fits well with the growth strategy of Celonic. Further investment plans to achieve a leading market position, not only ensures the continuation of more than 120 current jobs, but also provides a strong foundation for creation of future jobs at the site.”

Henner Kollenberg, Glycotope’s Managing Director, said "We look forward to embarking on a new chapter of cooperation with the site in Heidelberg. We are excited about the partnership with Celonic, shaped on CMO services as well as on further marketing of the GlycoExpress (GEX) human cell line platform. For Glycotope the transaction represents a further step in setting its strategic focus on the development of proprietary antibodies in the field of immune-oncology.”

Read More

Related news

Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more 
India to have strongest global growth in 2019?

India to have strongest global growth in 2019?

4 Dec 2018

Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.

Read more 
Catalent to expand biologics packaging capabilities

Catalent to expand biologics packaging capabilities

3 Dec 2018

Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.

Read more 
Merck successfully divests Consumer Health

Merck successfully divests Consumer Health

2 Dec 2018

Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

Read more 
Digital manufacturing is a top priority for life sciences

Digital manufacturing is a top priority for life sciences

29 Nov 2018

Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

Read more 
NIH to evaluate effectiveness of male contraceptive skin gel

NIH to evaluate effectiveness of male contraceptive skin gel

28 Nov 2018

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Read more 
QPS expands US-based Phase I clinical trial capabilities

QPS expands US-based Phase I clinical trial capabilities

27 Nov 2018

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Read more 
Hikma announces injectable licensing agreement

Hikma announces injectable licensing agreement

27 Nov 2018

Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

Read more